Not applicableStudy completedNCT04697160What this trial is testingObservational Retrospective Cohort Study of Systemic Therapies for R/R DLBCLWho this might be right forDiffuse Large B Cell Lymphoma MorphoSys AG 3,573
Testing effectiveness (Phase 2)Active Not RecruitingNCT05020015What this trial is testingTAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)Who this might be right forRelapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Takeda 27
Testing effectiveness (Phase 2)Study completedNCT00005040What this trial is testingArsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's LymphomaWho this might be right forLymphoma Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT05253118What this trial is testingRelapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)Who this might be right forDLBCL Seoul National University Hospital 28
Testing effectiveness (Phase 2)Ended earlyNCT02420717What this trial is testingRuxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaWho this might be right forRecurrent B Acute Lymphoblastic LeukemiaRecurrent Ph-Like Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia+1 more M.D. Anderson Cancer Center 11
Early research (Phase 1)Looking for participantsNCT06565689What this trial is testingEvaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012Who this might be right forRelapsed or Refractory B-Cell Non-Hodgkin Lymphoma Excyte Biopharma Ltd 48
Early research (Phase 1)Looking for participantsNCT06859008What this trial is testingZanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWho this might be right forChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more City of Hope Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT01118013What this trial is testingDonor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantWho this might be right forLeukemiaLymphomaLymphoproliferative Disorder+3 more Alliance for Clinical Trials in Oncology 6
Early research (Phase 1)Study completedNCT01429025What this trial is testingRituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin LymphomaWho this might be right forRefractory/Relapsed Indolent Non-Hodgkin Lymphoma Alliance for Clinical Trials in Oncology 26
Testing effectiveness (Phase 2)Looking for participantsNCT03676504What this trial is testingTreatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CARWho this might be right forAcute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, PediatricChronic Lymphocytic Leukemia+3 more University Hospital Heidelberg 68
Large-scale testing (Phase 3)Study completedNCT01014208What this trial is testingOfatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell LymphomaWho this might be right forLymphoma, Large-Cell, Diffuse GlaxoSmithKline 447
Very early researchNot Yet RecruitingNCT07168291What this trial is testingNovel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell LymphomaWho this might be right forDiffuse Large B Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Burkitt Lymphoma First Affiliated Hospital Xi'an Jiaotong University 3
Testing effectiveness (Phase 2)Study completedNCT00452374What this trial is testingOxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLLWho this might be right forLeukemia M.D. Anderson Cancer Center 48
Testing effectiveness (Phase 2)WithdrawnNCT04285268What this trial is testingRituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaWho this might be right forHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell Lymphoma+4 more Rutgers, The State University of New Jersey
Post-approval studies (Phase 4)Looking for participantsNCT06134284What this trial is testingClinical Study of OR for Second-line Treatment of Refractory MZLWho this might be right forOR Regimen for Relapsed/Refractory Marginal Zone Lymphoma Lixia Sheng 39
Testing effectiveness (Phase 2)Study completedNCT02399085What this trial is testingOpen Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCLWho this might be right forDiffuse Large B-cell Lymphoma MorphoSys AG 81
Testing effectiveness (Phase 2)Study completedNCT01076543What this trial is testingLenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaWho this might be right forAIDS-Related Hodgkin LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Follicular Lymphoma+5 more National Cancer Institute (NCI) 110
Early research (Phase 1)Not Yet RecruitingNCT07725406What this trial is testingLow-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaWho this might be right forRelapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM) Weill Medical College of Cornell University 32
Testing effectiveness (Phase 2)Looking for participantsNCT04186520What this trial is testingCAR-20/19-T Cells in Patients With Relapsed Refractory B Cell MalignanciesWho this might be right forNon Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more Medical College of Wisconsin 100
Large-scale testing (Phase 3)WithdrawnNCT06205290What this trial is testingCompare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesWho this might be right forLeukemia, Lymphocytic, Chronic, B-Cell Juno Therapeutics, Inc., a Bristol-Myers Squibb Company